Pfizer Representative Personal Data Clause Samples

Pfizer Representative Personal Data. If in the support of a clinical trial, Pfizer representatives are required to submit to Institution or Principal Investigator any Personal Data, including but not limited to, name, address, phone number, government identifier, or birthdate (“Pfizer Representative Personal Data”), Institution and Principal Investigator will: 12.2 Osobní údaje zástupců společnosti Pfizer. Pokud je v průběhu klinického hodnocení požadováno, aby zástupci společnosti Pfizer předali Instituci své Osobní údaje, včetně, ale ne výlučně, jména adresy, telefonního čísla, identifikačního čísla nebo data narození („Osobní údaje zástupců společnosti Pfizer“), Instituce bude postupovat následujícím způsobem: a. protect the confidentiality of Pfizer Representative Personal Data using the same or similar standards Institution and, if applicable, Principal Investigator use for their own employees; a. ochrání důvěrnost Osobních údajů zástupců společnosti Pfizer použitím stejných nebo podobných opatření, které používá pro své vlastní zaměstnance; b. not sell or disclose Pfizer Representative Personal Data to any third party except as required by law; b. neprodá ani nezpřístupní Osobní údaje zástupců společnosti Pfizer žádné třetí straně s výjimkou případů vyžadovaných zákonem; c. impose similar confidentiality and security obligations, by contract, on any contracted service providers with whom Institution or Principal Investigator may share Pfizer Representative Personal Data; c. ustanoví ve smlouvě obdobné povinnosti ohledně důvěrnosti a zabezpečení těchto údajů vůči všem poskytovatelům služeb, se kterými by Instituce mohla Osobní údaje zástupců společnosti Pfizer sdílet;
View SourceView Similar (3)
Pfizer Representative Personal Data. If in the support of a clinical trial, Pfizer representatives are required to submit to Institution Personal Data, including but not limited to, name, address, phone number, government identifier, or birthdate (“Pfizer Representative Personal Data”), Institution will: a. protect the confidentiality of Pfizer Representative Personal Data using the same or similar standards Institution uses for its own employees; 12.2 Osobní údaje zástupců společnosti Pfizer. Pokud je v průběhu klinického hodnocení požadováno, aby zástupci společnosti Pfizer předali Instituci své osobní údaje, včetně, ale ne výlučně, jména adresy, telefonního čísla, identifikačního čísla nebo data narození („Osobní údaje zástupců společnosti Pfizer“), Instituce bude postupovat následujícím způsobem: a. ochrání důvěrnost Osobních údajů zástupců společnosti Pfizer použitím stejných nebo podobných opatření, které používá pro své vlastní zaměstnance; b. not sell or disclose Pfizer Representative Personal Data to any third party except as required by law; c. impose similar confidentiality and security obligations, by contract, on any contracted service providers with whom Institution may share Pfizer Representative Personal Data; d. take appropriate measures to protect against any unauthorized use or disclosure of Pfizer Representative Personal Data and will promptly notify Pfizer of any breach of this provision. b. neprodá ani nezpřístupní Osobní údaje zástupců společnosti Pfizer žádné třetí straně s výjimkou případů vyžadovaných zákonem; c. ustanoví ve smlouvě obdobné povinnosti ohledně důvěrnosti a zabezpečení těchto údajů vůči všem poskytovatelům služeb, se kterými by Instituce mohla Osobní údaje zástupců společnosti Pfizer sdílet; d. přijme příslušná opatření k ochraně proti neoprávněnému použití nebo zpřístupnění Osobních údajů zástupců společnosti Pfizer a bez prodlení bude společnost Pfizer informovat o jakémkoliv porušení tohoto ustanovení.
View SourceView Similar (2)
Pfizer Representative Personal Data. If in the support of a clinical trial, Pfizer representatives are required to submit to Institution any Personal Data, including but not limited to, name, address, phone number, government identifier, or birthdate (“Pfizer Representative Personal Data”), Institution and Principal Investigator will: 12.2 Osobní údaje zástupců společnosti Pfizer. Pokud zástupci společnosti Pfizer musí v rámci podpory klinického hodnocení předložit zdravotnickému zařízení jakékoli osobní údaje, mimo jiné včetně jména, adresy, telefonního čísla, rodného čísla nebo data narození (dále jen „osobní údaje zástupců společnosti Pfizer“), zdravotnické zařízení a hlavní zkoušející: a. protect the confidentiality of Pfizer Representative Personal Data using the same or similar standards Institution uses and if applicable Principal Investigator use for its own employees; a. zajistí ochranu důvěrných osobních údajů zástupců společnosti Pfizer použitím stejných nebo podobných standardů, které zdravotnické zařízení a případně i hlavní zkoušející používají u svých vlastních zaměstnanců,
View SourceView Similar (2)
Pfizer Representative Personal Data. If in the support of a clinical trial, Pfizer representatives are required to submit to Institution Personal Data, including but not limited to, name, address, phone number, government identifier, or birthdate (“Pfizer Representative Personal Data”), Institution will: a. protect the confidentiality of Pfizer Representative Personal Data using the same or similar standards Institution uses for its own employees; b. not sell or disclose Pfizer Representative Personal Data to any third party except as required by law;
View SourceView Similar (2)
Pfizer Representative Personal Data. If in the support of a clinical trial, Pfizer representatives are required to submit to Contractor any personally identifying information (Personal Data), including but not limited to, name, address, phone number, government identifier, or birthdate (“Pfizer Representative Personal Data”), Contractor will:
View Source
Pfizer Representative Personal Data. If in the support of a clinical trial, Pfizer representatives are required to submit to Institution any Personal Data, including but not limited to, name, address, phone number, government identifier, or birthdate (“Pfizer Representative Personal Data”), Institution will: a. protect the confidentiality of Pfizer Representative Personal Data using the same or similar standards Institution uses for its own employees; b. not sell or disclose Pfizer Representative Personal Data to any third party except as required by law; c. impose similar confidentiality and security obligations, by contract, on any contracted service providers with whom Institution may share Pfizer Representative Personal Data; monitorovania, ktoré by mohli ovplyvniť bezpečnosť účastníkov alebo vykonávanie klinického skúšania. Hlavný skúšajúci súhlasí, že bude zdieľať tieto informácie s inštitúciou a môže informovať účastníkov klinického skúšania o takýchto zisteniach, ak je to vhodné.
View Source
Pfizer Representative Personal Data. If in the support of a clinical trial, Pfizer representatives are required to
View Source
Pfizer Representative Personal Data. If in the support of a clinical trial, Pfizer representatives are required to submit to Institution or Principal Investigator any Personal Data, including but not limited to, name, address, phone number, government identifier, or birthdate (“Pfizer Representative Personal Data”), Institution and Principal Investigator will: protect the confidentiality of Pfizer Representative Personal Data using the same or similar standards Institution and, if applicable, Principal Investigator use for their own employees; not sell or disclose Pfizer Representative Personal Data to any third party except as required by law; impose similar confidentiality and security obligations, by contract, on any contracted service providers with whom Institution or Principal Investigator may share Pfizer Representative Personal Data; take appropriate measures to protect against any unauthorized access use or disclosure of Pfizer Representative Personal Data and will promptly notify Pfizer of any breach of this provision. Inspections and Audits. Principal Investigator and Institution acknowledge that the Study is subject to inspection by regulatory authorities worldwide, including the United States FDA, and that such inspections may occur after completion of the Study and may include auditing of Study Records. Pfizer may also audit Study Records during or after the Study as part of its monitoring of Study conduct.
View Source

Related to Pfizer Representative Personal Data

  • Shared Personal Data This clause sets out the framework for the sharing of personal data between the parties as data controllers. Each party acknowledges that one party (the Data Discloser) will regularly disclose to the other party (the Data Recipient) Shared Personal Data collected by the Data Discloser for the Agreed Purposes.

  • Processing Personal Data This ▇▇▇▇▇ shall be completed by the Controller, who may take account of the view of the Processors, however the final decision as to the content of this Annex shall be with the Buyer at its absolute discretion.

  • Service Personal Data The Personal Data supplied by a Buyer to the Supplier in the course of the use of the G-Cloud Services for purposes of or in connection with this Call-Off Contract. Spend controls The approval process used by a central government Buyer if it needs to spend money on certain digital or technology services, see ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇/service-manual/agile-delivery/spend-controls- check-if-you-need-approval-to-spend-money-on-a-service Start date The Start date of this Call-Off Contract as set out in the Order Form. Subcontract Any contract or agreement or proposed agreement between the Supplier and a subcontractor in which the subcontractor agrees to provide to the Supplier the G-Cloud Services or any part thereof or facilities or goods and services necessary for the provision of the G- Cloud Services or any part thereof. Subcontractor Any third party engaged by the Supplier under a subcontract (permitted under the Framework Agreement and the Call-Off Contract) and its servants or agents in connection with the provision of G-Cloud Services. Subprocessor Any third party appointed to process Personal Data on behalf of the Supplier under this Call-Off Contract. Supplier The person, firm or company identified in the Order Form. Supplier Representative The representative appointed by the Supplier from time to time in relation to the Call-Off Contract. Supplier staff All persons employed by the Supplier together with the Supplier’s servants, agents, suppliers and subcontractors used in the performance of its obligations under this Call-Off Contract. Supplier terms The relevant G-Cloud Service terms and conditions as set out in the Terms and Conditions document supplied as part of the Supplier’s Application. Term The term of this Call-Off Contract as set out in the Order Form. Variation This has the meaning given to it in clause 32 (Variation process). Working Days Any day other than a Saturday, Sunday or public holiday in England and Wales. Year A contract year. Schedule 7: GDPR Information This schedule reproduces the annexes to the GDPR schedule contained within the Framework Agreement and incorporated into this Call-off Contract. Annex 1: Processing Personal Data This ▇▇▇▇▇ shall be completed by the Controller, who may take account of the view of the Processors, however the final decision as to the content of this Annex shall be with the Buyer at its absolute discretion.

  • Your Personal Data If you determine that you will be supplying us with your Personal Data (as defined in the Data Processing Addendum referenced below) for us to process on your behalf, in the provision of maintenance and support services or hosting services (if the Product licensed to you is a Hosted Service) or during the course of any audits we conduct pursuant to section 1.14 (Audit), you may submit a written request at ▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇.▇▇▇ for the mutual execution of a Data Processing Addendum substantially in the form we make available at ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇.▇▇▇/docs/default-source/progress-software/data-processing-addendum.pdf and we will enter into such Data Processing Addendum with you. To the extent there is any conflict between this ▇▇▇▇ and such Data Processing Addendum, the Data Processing Addendum will prevail with respect to our handling and processing of your Personal Data.

  • Handling Sensitive Personal Information and Breach Notification A. As part of its contract with HHSC Contractor may receive or create sensitive personal information, as section 521.002 of the Business and Commerce Code defines that phrase. Contractor must use appropriate safeguards to protect this sensitive personal information. These safeguards must include maintaining the sensitive personal information in a form that is unusable, unreadable, or indecipherable to unauthorized persons. Contractor may consult the “Guidance to Render Unsecured Protected Health Information Unusable, Unreadable, or Indecipherable to Unauthorized Individuals” issued by the U.S. Department of Health and Human Services to determine ways to meet this standard. B. Contractor must notify HHSC of any confirmed or suspected unauthorized acquisition, access, use or disclosure of sensitive personal information related to this Contract, including any breach of system security, as section 521.053 of the Business and Commerce Code defines that phrase. Contractor must submit a written report to HHSC as soon as possible but no later than 10 business days after discovering the unauthorized acquisition, access, use or disclosure. The written report must identify everyone whose sensitive personal information has been or is reasonably believed to have been compromised. C. Contractor must either disclose the unauthorized acquisition, access, use or disclosure to everyone whose sensitive personal information has been or is reasonably believed to have been compromised or pay the expenses associated with HHSC doing the disclosure if: 1. Contractor experiences a breach of system security involving information owned by HHSC for which disclosure or notification is required under section 521.053 of the Business and Commerce Code; or 2. Contractor experiences a breach of unsecured protected health information, as 45 C.F.R. §164.402 defines that phrase, and HHSC becomes responsible for doing the notification required by 45 C.F.R. §164.404. HHSC may, at its discretion, waive Contractor's payment of expenses associated with HHSC doing the disclosure.